Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru

Descripción del Articulo

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin lymphoma in adults, with a high mortality rate. Low serum albumin can be a biological indicator of the disease reflected as increased inflammation or increased toxicities. Currently, the International Progn...

Descripción completa

Detalles Bibliográficos
Autores: Morales-Cuzquén , Luis Gustavo, Vela-Ruiz, José Manuel, Ferrer-Ponce, Diana I., Fernandez-Anccas , Cesar, Roldán-Arbieto, Luis, Beltrán-Garate , Brady Ernesto, Villela, Luis, De La Cruz-Vargas, Jhony A.
Formato: artículo
Fecha de Publicación:2024
Institución:Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
Repositorio:Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
Lenguaje:español
OAI Identifier:oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/2225
Enlace del recurso:https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/2225
Nivel de acceso:acceso abierto
Materia:Linfoma de Células B Grandes Difuso
Pronóstico
Albúmina
Supervivencia
Biomarcadores
Diffuse Large B-Cell Lymphoma
Prognosis
Albumin
Survival
Biomarkers
id REVCMH_5dc75a6aefa1d1d33a405450ab1c7430
oai_identifier_str oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/2225
network_acronym_str REVCMH
network_name_str Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
repository_id_str
dc.title.none.fl_str_mv Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru
Albúmina como factor pronóstico en sobrevida de pacientes con linfoma difuso de células B grande atendidos en un hospital de Lima, Perú
title Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru
spellingShingle Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru
Morales-Cuzquén , Luis Gustavo
Linfoma de Células B Grandes Difuso
Pronóstico
Albúmina
Supervivencia
Biomarcadores
Diffuse Large B-Cell Lymphoma
Prognosis
Albumin
Survival
Biomarkers
title_short Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru
title_full Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru
title_fullStr Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru
title_full_unstemmed Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru
title_sort Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, Peru
dc.creator.none.fl_str_mv Morales-Cuzquén , Luis Gustavo
Vela-Ruiz, José Manuel
Ferrer-Ponce, Diana I.
Fernandez-Anccas , Cesar
Roldán-Arbieto, Luis
Beltrán-Garate , Brady Ernesto
Villela, Luis
De La Cruz-Vargas, Jhony A.
author Morales-Cuzquén , Luis Gustavo
author_facet Morales-Cuzquén , Luis Gustavo
Vela-Ruiz, José Manuel
Ferrer-Ponce, Diana I.
Fernandez-Anccas , Cesar
Roldán-Arbieto, Luis
Beltrán-Garate , Brady Ernesto
Villela, Luis
De La Cruz-Vargas, Jhony A.
author_role author
author2 Vela-Ruiz, José Manuel
Ferrer-Ponce, Diana I.
Fernandez-Anccas , Cesar
Roldán-Arbieto, Luis
Beltrán-Garate , Brady Ernesto
Villela, Luis
De La Cruz-Vargas, Jhony A.
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Linfoma de Células B Grandes Difuso
Pronóstico
Albúmina
Supervivencia
Biomarcadores
Diffuse Large B-Cell Lymphoma
Prognosis
Albumin
Survival
Biomarkers
topic Linfoma de Células B Grandes Difuso
Pronóstico
Albúmina
Supervivencia
Biomarcadores
Diffuse Large B-Cell Lymphoma
Prognosis
Albumin
Survival
Biomarkers
description Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin lymphoma in adults, with a high mortality rate. Low serum albumin can be a biological indicator of the disease reflected as increased inflammation or increased toxicities. Currently, the International Prognostic Index (IPI) is the accepted model for prognosis in patients with DLBCL. Objective: To determine the prognostic value of albumin in overall survival (OS) of patients with DLBCL treated with immunochemotherapy in a hospital in Peru during the period 2017-2019. Materials and methods: Analytical, cross-sectional, retrospective and observational study. It consisted of 161 patients with DLBCL diagnosed and treated during the mentioned period. The SPSS v27 program was used for statistical analysis. Hazard ratios (HR) and 95% confidence intervals (CI) were used to assess the prognostic impact of albumin on overall survival (OS). Results: The OS of patients up to 12 months was 94%, 3 years was 87%, and 5 years was 87%. In multivariate Cox proportional hazards regression analysis, albumin (p=0.037; HR=3.614 95% CI [1.079 – 12.105]) and IPI (p=0.017; HR 1.891 95% CI [1.121 – 3.19]) were found to be the independent variables influencing OS in patients with DLBCL. Conclusions: Hypoalbuminemia might be a risk factor for shorter OS. In association with the IPI, a cumulative prognostic scoring system could be developed in patients with DLBCL.
publishDate 2024
dc.date.none.fl_str_mv 2024-11-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/2225
10.35434/rcmhnaaa.2024.174.2225
url https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/2225
identifier_str_mv 10.35434/rcmhnaaa.2024.174.2225
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/2225/964
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo
publisher.none.fl_str_mv Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo
dc.source.none.fl_str_mv Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 17 No. 4 (2024): Rev. Cuerpo Med. HNAAA, October - December; e2225
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 17 Núm. 4 (2024): Rev. Cuerpo Med. HNAAA, Octubre - Diciembre; e2225
2227-4731
2225-5109
10.35434/rcmhnaaa.2024.174
reponame:Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
instname:Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
instacron:HNAAA
instname_str Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
instacron_str HNAAA
institution HNAAA
reponame_str Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
collection Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1842629794589573120
spelling Albumin as a prognostic factor in the survival of patients with diffuse large B-cell lymphoma treated at a hospital in Lima, PeruAlbúmina como factor pronóstico en sobrevida de pacientes con linfoma difuso de células B grande atendidos en un hospital de Lima, PerúMorales-Cuzquén , Luis GustavoVela-Ruiz, José ManuelFerrer-Ponce, Diana I.Fernandez-Anccas , CesarRoldán-Arbieto, LuisBeltrán-Garate , Brady Ernesto Villela, LuisDe La Cruz-Vargas, Jhony A.Linfoma de Células B Grandes DifusoPronósticoAlbúminaSupervivenciaBiomarcadoresDiffuse Large B-Cell LymphomaPrognosisAlbuminSurvivalBiomarkersIntroduction: Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin lymphoma in adults, with a high mortality rate. Low serum albumin can be a biological indicator of the disease reflected as increased inflammation or increased toxicities. Currently, the International Prognostic Index (IPI) is the accepted model for prognosis in patients with DLBCL. Objective: To determine the prognostic value of albumin in overall survival (OS) of patients with DLBCL treated with immunochemotherapy in a hospital in Peru during the period 2017-2019. Materials and methods: Analytical, cross-sectional, retrospective and observational study. It consisted of 161 patients with DLBCL diagnosed and treated during the mentioned period. The SPSS v27 program was used for statistical analysis. Hazard ratios (HR) and 95% confidence intervals (CI) were used to assess the prognostic impact of albumin on overall survival (OS). Results: The OS of patients up to 12 months was 94%, 3 years was 87%, and 5 years was 87%. In multivariate Cox proportional hazards regression analysis, albumin (p=0.037; HR=3.614 95% CI [1.079 – 12.105]) and IPI (p=0.017; HR 1.891 95% CI [1.121 – 3.19]) were found to be the independent variables influencing OS in patients with DLBCL. Conclusions: Hypoalbuminemia might be a risk factor for shorter OS. In association with the IPI, a cumulative prognostic scoring system could be developed in patients with DLBCL.Introducción: El linfoma difuso de células B grandes (LDCGB) es la forma más prevalente del linfoma no Hodgkin en adultos, tiene una alta tasa de mortalidad. La albumina sérica baja puede ser un indicador biológico de la enfermedad reflejado como un aumento de la inflamación o aumento en toxicidades. Actualmente el Índice Pronóstico Internacional (IPI) es el modelo aceptado para pronóstico en pacientes con LDCGB. Objetivo: Determinar el valor pronóstico de la albumina en la supervivencia global (SG) de pacientes con LDCGB tratados con inmunoquimioterapia en un hospital de Perú durante el período 2017–2019. Material y método: Estudio analítico, transversal, retrospectivo y observacional. Constó con 161 pacientes con LDCGB diagnosticados y tratados durante el periodo mencionado. Se utilizó el programa SPSS v27 para el análisis estadístico. Se utilizaron cocientes de riesgos (HR) e intervalos de confianza (IC) del 95 %, para evaluar el impacto pronóstico de la albúmina en la supervivencia global (SG). Resultados: La SG de pacientes fue de hasta 12 meses del 94%, de 3 años fue 87% y de 5 años fue del 87%. En el análisis multivariado de regresión de riesgos proporcionales Cox, se observó que la albúmina (p=0,037; HR=3.614 IC 95% [ 1.079 – 12.105]) y el IPI (p=0,017; HR 1.891 IC 95% [1.121 – 3.19]) fueron las variables independientes con influjo en la SG de los pacientes con LDCGB. Conclusiones: La hipoalbuminemia podría ser un factor de riesgo para una SG más corta. Asociado con el IPI, se podría desarrollar un sistema de puntuación pronóstico acumulativo en pacientes con LDCGB.Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo2024-11-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/222510.35434/rcmhnaaa.2024.174.2225Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 17 No. 4 (2024): Rev. Cuerpo Med. HNAAA, October - December; e2225Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 17 Núm. 4 (2024): Rev. Cuerpo Med. HNAAA, Octubre - Diciembre; e22252227-47312225-510910.35434/rcmhnaaa.2024.174reponame:Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjoinstname:Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjoinstacron:HNAAAspahttps://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/2225/964Derechos de autor 2024 Luis Gustavo Morales-Cuzquén , José Manuel Vela-Ruiz, Diana I. Ferrer-Ponce, Cesar Fernandez-Anccas , Luis Roldán-Arbieto, Brady Ernesto Beltrán-Garate , Luis Villela, Jhony A. De La Cruz-Vargashttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/22252025-05-19T04:52:26Z
score 12.641649
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).